ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Impact BioMedical (IBO)
Impact BioMedical stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NYSE
$3.55▼ -4.83%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
42%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Impact BioMedical in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Impact BioMedical
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Impact BioMedical a 42% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $2.66 and $4.16; in 9 out of 10, between $1.79 and $6.19. Estimated annual volatility is 138%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $45.5M
- P/E ratio
- 57.5
- 52-week high
- $10.51
- 52-week low
- $2.43
- Revenue (12 months)
- $0.0M
- Return on equity
- 23.5%
- Free cash flow (12 months)
- $1.0M
- Beta
- 2.76
What this means
ATLAS does not publish a fair value for IBO right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks IBO has traded between $2.43 and $10.51. Today it is 66.2% below that high and 46% above its low.
Its beta is 2.76: it tends to move more than the market, both up and down.
About the company
Impact BioMedical Inc. is a biotechnology company focused on discovering, validating, and commercializing science-based products and technologies for human healthcare and wellness.
Want to see everything about Impact BioMedical?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Impact BioMedical do?
Impact BioMedical Inc. is a biotechnology company focused on discovering, validating, and commercializing science-based products and technologies for human healthcare and wellness.
What is the chance IBO goes up next month?
42%: somewhat worse than a coin flip. In half of the simulated outcomes, IBO ends the month between $2.66 and $4.16.
How big is Impact BioMedical and what is its P/E ratio?
Impact BioMedical's market capitalization is $45.5M. Its price-to-earnings (P/E) ratio is 57.5: you pay $57.5 for each $1 of yearly earnings.
How volatile is IBO?
ATLAS estimates annual volatility at 138%. In a typical month, half of the outcomes end between $2.66 and $4.16.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer